Moving towards personalized treatments of immune-related adverse events

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155

Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells

Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T. B., Oukka, M., Weiner, H. L., & Kuchroo, V. K. (2006) · Nature · doi:10.1038/nature04753 · Cited by 6,992

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors

Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671

Role of the microbiota in immunity and inflammation.

Belkaid, Y., & Hand, T. W. (2014) · Cell · doi:10.1016/j.cell.2014.03.011 · Cited by 5,385

Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients

Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812

An endotoxin-induced serum factor that causes necrosis of tumors

Carswell, E. A., Old, L. J., Kassel, R. L., Green, S., Fiore, N., & Williamson, B. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.9.3666 · Cited by 4,532

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Ernstoff, M. S., Gardner, J. M., Ginex, P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6385 · Cited by 3,713

Mechanisms of type-I- and type-II-interferon-mediated signalling

Platanias, L. C. (2005) · Nature reviews. Immunology · doi:10.1038/nri1604 · Cited by 3,631

Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota

Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P. M., et al. (2015) · Science · doi:10.1126/science.aad1329 · Cited by 3,488

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237

Transforming growth factor-β induces development of the TH17 lineage

Mangan, P. R., Harrington, L. E., O'Quinn, D. B., Helms, W. S., Bullard, D. C., Elson, C. O., Hatton, R. D., Wahl, S. M., Schoeb, T. R., & Weaver, C. T. (2006) · Nature · doi:10.1038/nature04754 · Cited by 3,087

B cells and tertiary lymphoid structures promote immunotherapy response

Helmink, B. A., Reddy, S. M., Gao, J., Zhang, S., Basar, R., Thakur, R., Yizhak, K., Sade-Feldman, M., Blando, J., Han, G., et al. (2020) · Nature · doi:10.1038/s41586-019-1922-8 · Cited by 2,731

Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis

Wang, D. Y., Salem, J.-E., Cohen, J. V., Chandra, S., Menzer, C., Ye, F., Zhao, S., Das, S., Beckermann, K. E., Ha, L., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.3923 · Cited by 2,674

Tertiary lymphoid structures improve immunotherapy and survival in melanoma

Cabrita, R., Lauss, M., Sanna, A., Donia, M., Skaarup Larsen, M., Mitra, S., Johansson, I., Phung, B., Harbst, K., Vallon-Christersson, J., et al. (2020) · Nature · doi:10.1038/s41586-019-1914-8 · Cited by 2,374

Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Haanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx225 · Cited by 2,367

Fulminant Myocarditis with Combination Immune Checkpoint Blockade

Johnson, D. B., Balko, J. M., Compton, M. L., Chalkias, S., Gorham, J., Xu, Y., Hicks, M., Puzanov, I., Alexander, M. R., Bloomer, T. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609214 · Cited by 2,308

IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer

Grivennikov, S., Karin, E., Terzic, J., Mucida, D., Yu, G.-Y., Vallabhapurapu, S., Scheller, J., Rose-John, S., Cheroutre, H., Eckmann, L., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.001 · Cited by 2,155

Gut microbiome structure and metabolic activity in inflammatory bowel disease

Franzosa, E. A., Sirota-Madi, A., Avila-Pacheco, J., Fornelos, N., Haiser, H. J., Reinker, S., Vatanen, T., Hall, A. B., Mallick, H., McIver, L. J., et al. (2018) · Nature Microbiology · doi:10.1038/s41564-018-0306-4 · Cited by 1,995

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

on behalf of the Society for Immunotherapy of Cancer Toxicity Management Working Group, Puzanov, I., Diab, A., Abdallah, K., Bingham, C. O., Brogdon, C., Dadu, R., Hamad, L., Kim, S., Lacouture, M. E., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0300-z · Cited by 1,992

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression

Garcia-Diaz, A., Shin, D. S., Moreno, B. H., Saco, J., Escuin-Ordinas, H., Rodriguez, G. A., Zaretsky, J. M., Sun, L., Hugo, W., Wang, X., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.04.031 · Cited by 1,942

B cells are associated with survival and immunotherapy response in sarcoma

Petitprez, F., de Reyniès, A., Keung, E. Z., Chen, T. W.-W., Sun, C.-M., Calderaro, J., Jeng, Y.-M., Hsiao, L.-P., Lacroix, L., Bougoüin, A., et al. (2020) · Nature · doi:10.1038/s41586-019-1906-8 · Cited by 1,942

Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases

Dinarello, C. A., Simon, A., & van der Meer, J. W. M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3800 · Cited by 1,812

Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

Sandborn, W. J., Su, C. G., Sands, B. E., D’Haens, G., Vermeire, S., Schreiber, S., Danese, S., Feagan, B. G., Reinisch, W., Niezychowski, W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1606910 · Cited by 1,783

Interferons, immunity and cancer immunoediting

Dunn, G. P., Koebel, C. M., & Schreiber, R. D. (2006) · Nature Reviews Immunology · doi:10.1038/nri1961 · Cited by 1,617

Interleukin-1 and IL-23 Induce Innate IL-17 Production from γδ T Cells, Amplifying Th17 Responses and Autoimmunity

Sutton, C. E., Lalor, S. J., Sweeney, C. M., Brereton, C. F., Lavelle, E. C., & Mills, K. H. G. (2009) · Immunity · doi:10.1016/j.immuni.2009.08.001 · Cited by 1,553

The IL-1 family: regulators of immunity

Sims, J. E., & Smith, D. E. (2010) · Nature reviews. Immunology · doi:10.1038/nri2691 · Cited by 1,459

Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs

Haslam, A., & Prasad, V. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.2535 · Cited by 1,413

Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations

Shin, D. S., Zaretsky, J. M., Escuin-Ordinas, H., Garcia-Diaz, A., Hu-Lieskovan, S., Kalbasi, A., Grasso, C. S., Hugo, W., Sandoval, S., Torrejon, D. Y., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1223 · Cited by 1,337

Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab

Chaput, N., Lepage, P., Coutzac, C., Soularue, E., Le Roux, K., Monot, C., Boselli, L., Routier, E., Cassard, L., Collins, M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx108 · Cited by 1,310

Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy

Naidoo, J., Wang, X., Woo, K. M., Iyriboz, T., Halpenny, D., Cunningham, J., Chaft, J. E., Segal, N. H., Callahan, M. K., Lesokhin, A. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.2005 · Cited by 1,215

Immunomodulation of Autoimmune and Inflammatory Diseases with Intravenous Immune Globulin

Kazatchkine, M. D., & Kaveri, S. V. (2001) · New England Journal of Medicine · doi:10.1056/nejmra993360 · Cited by 1,212

Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors

Hirano, T., Ishihara, K., & Hibi, M. (2000) · Oncogene · doi:10.1038/sj.onc.1203551 · Cited by 1,207

Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma

Weber, J. S., Hodi, F. S., Wolchok, J. D., Topalian, S. L., Schadendorf, D., Larkin, J., Sznol, M., Long, G. V., Li, H., Waxman, I. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2015.66.1389 · Cited by 1,158

Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer.

Arbour, K. C., Mezquita, L., Long, N., Rizvi, H., Auclin, E., Ni, A., Martínez-Bernal, G., Ferrara, R., Lai, W. V., Hendriks, L. E. L., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.79.0006 · Cited by 1,071

Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center

Horvat, T. Z., Adel, N. G., Dang, T.-O., Momtaz, P., Postow, M. A., Callahan, M. K., Carvajal, R. D., Dickson, M. A., D'Angelo, S. P., Woo, K. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.60.8448 · Cited by 1,064

Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis

Dubin, K., Callahan, M. K., Ren, B., Khanin, R., Viale, A., Ling, L., No, D., Gobourne, A., Littmann, E., Huttenhower, C., et al. (2016) · Nature Communications · doi:10.1038/ncomms10391 · Cited by 987

Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review

Khoja, L., Day, D., Chen, T. W., Siu, L. L., & Hansen, A. R. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx286 · Cited by 952

IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases

Teng, M. W. L., Bowman, E. P., McElwee, J. J., Smyth, M. J., Casanova, J., Cooper, A. M., & Cua, D. J. (2015) · Nature Medicine · doi:10.1038/nm.3895 · Cited by 905

Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer

Lesina, M., Kurkowski, M. U., Ludes, K., Rose-John, S., Treiber, M., Klöppel, G., Yoshimura, A., Reindl, W., Sipos, B., Akira, S., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.03.009 · Cited by 862

A Proposed Classification of the Immunological Diseases

McGonagle, D., & McDermott, M. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030297 · Cited by 841

Regulation of Immune Responses by mTOR

Powell, J. D., Pollizzi, K. N., Heikamp, E. B., & Horton, M. R. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-075024 · Cited by 836

Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade

Hsu, J., Hodgins, J. J., Marathe, M., Nicolai, C. J., Bourgeois-Daigneault, M.-C., Trevino, T. N., Azimi, C. S., Scheer, A. K., Randolph, H. E., Thompson, T. W., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci99317 · Cited by 817

Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis

Wang, Y., Wiesnoski, D. H., Helmink, B. A., Gopalakrishnan, V., Choi, K., DuPont, H. L., Jiang, Z.-D., Abu-Sbeih, H., Sanchez, C. A., Chang, C.-C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0238-9 · Cited by 740

Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody

Iwama, S., De Remigis, A., Callahan, M. K., Slovin, S. F., Wolchok, J. D., & Caturegli, P. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008002 · Cited by 715

Tofacitinib versus methotrexate in rheumatoid arthritis

Lee, E. B., Fleischmann, R., Hall, S., Wilkinson, B., Bradley, J. D., Gruben, D., Koncz, T., Krishnaswami, S., Wallenstein, G. V., Zang, C., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1310476 · Cited by 711

Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)

Ghoreschi, K., Jesson, M. I., Xiong, L., Lee, J. L., Ghosh, S., Alsup, J. W., Warner, J. D., Tanaka, M., Steward-Tharp, S. M., Gadina, M., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003668 · Cited by 651

Dermatologic Reactions to Immune Checkpoint Inhibitors

Sibaud, V. (2017) · American Journal of Clinical Dermatology · doi:10.1007/s40257-017-0336-3 · Cited by 640

Molecular mimicry and autoimmunity

Rojas, M., Restrepo-Jiménez, P., Monsalve, D. M., Pacheco, Y., Acosta-Ampudia, Y., Ramírez-Santana, C., Leung, P. S. C., Ansari, A. A., Gershwin, M. E., & Anaya, J.-M. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.10.012 · Cited by 627

The pathogenicity of Th17 cells in autoimmune diseases

Yasuda, K., Takeuchi, Y., & Hirota, K. (2019) · Seminars in Immunopathology · doi:10.1007/s00281-019-00733-8 · Cited by 586

IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer

Mace, T. A., Shakya, R., Pitarresi, J. R., Swanson, B. J., McQuinn, C. W., Loftus, S. N., Nordquist, E., Cruz‐Monserrate, Z., Yu, L., Young, G. S., et al. (2016) · Gut · doi:10.1136/gutjnl-2016-311585 · Cited by 541

Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway

Wei, L.-H., Kuo, M.-L., Chen, C.-A., Chou, C.-H., Lai, K.-B., Lee, C.-N., & Hsieh, C.-Y. (2003) · Oncogene · doi:10.1038/sj.onc.1206226 · Cited by 536

When worlds collide: Th17 and Treg cells in cancer and autoimmunity

Knochelmann, H. M., Dwyer, C. J., Bailey, S. R., Amaya, S. M., Elston, D. M., Mazza-McCrann, J. M., & Paulos, C. M. (2018) · Cellular & Molecular Immunology · doi:10.1038/s41423-018-0004-4 · Cited by 535

Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis

Papp, K. A., Blauvelt, A., Bukhalo, M., Gooderham, M., Krueger, J. G., Lacour, J. ‐., Menter, A., Philipp, S., Sofen, H. L., Tyring, S. K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1607017 · Cited by 532

The Role of IL-17 and related cytokines in inflammatory autoimmune diseases

Kuwabara, T., Ishikawa, F., Kondo, M., & Kakiuchi, T. (2017) · Mediators of Inflammation · doi:10.1155/2017/3908061 · Cited by 519

Autoinflammatory Disease Reloaded: A Clinical Perspective

Kastner, D. L., Aksentijevich, I. A., & Goldbach‐Mansky, R. T. (2010) · Cell · doi:10.1016/j.cell.2010.03.002 · Cited by 513

The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond

Brembilla, N. C., Senra, L., & Boehncke, W. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01682 · Cited by 491

Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease: A Systematic Review

Abdel-Wahab, N., Shah, M., Lopez-Olivo, M. A., & Suarez-Almazor, M. E. (2018) · Annals of Internal Medicine · doi:10.7326/m17-2073 · Cited by 487

High‐dose glucocorticoids for the treatment of ipilimumab‐induced hypophysitis is associated with reduced survival in patients with melanoma

Faje, A. T., Lawrence, D., Flaherty, K., Freedman, C., Fadden, R., Rubin, K., Cohen, J., & Sullivan, R. J. (2018) · Cancer · doi:10.1002/cncr.31629 · Cited by 486

Mechanisms of action of mycophenolate mofetil

Allison, A. (2005) · Lupus · doi:10.1177/096120330501400102 · Cited by 480

Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy

Perez-Ruiz, E., Minute, L., Otano, I., Alvarez, M., Ochoa, M. C., Belsue, V., de Andrea, C., Rodriguez-Ruiz, M. E., Perez-Gracia, J. L., Marquez-Rodas, I., et al. (2019) · Nature · doi:10.1038/s41586-019-1162-y · Cited by 480

The Coinhibitory Receptor CTLA-4 Controls B Cell Responses by Modulating T Follicular Helper, T Follicular Regulatory, and T Regulatory Cells

Sage, P. T., Paterson, A. M., Lovitch, S. B., & Sharpe, A. H. (2014) · Immunity · doi:10.1016/j.immuni.2014.12.005 · Cited by 450

Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III , Double‐Blind, Randomized Controlled Trial

Fleischmann, R., Pangan, A. L., Song, I., Mysler, E., Bessette, L., PETERFY, C. G., Durez, P., Östör, A. J. K., Li, Y., Zhou, Y., et al. (2019) · Arthritis & Rheumatology · doi:10.1002/art.41032 · Cited by 446

Is autoimmunity the Achilles' heel of cancer immunotherapy?

June, C. H., Warshauer, J. T., & Bluestone, J. A. (2017) · Nature Medicine · doi:10.1038/nm.4321 · Cited by 445

Abatacept for Severe Immune Checkpoint Inhibitor–Associated Myocarditis

Salem, J.-E., Allenbach, Y., Vozy, A., Brechot, N., Johnson, D. B., Moslehi, J. J., & Kerneis, M. (2019) · New England Journal of Medicine · doi:10.1056/nejmc1901677 · Cited by 443

Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4–insufficient subjects

Schwab, C., Gabrysch, A., Olbrich, P., Patiño, V., Warnatz, K., Wolff, D., Hoshino, A., Kobayashi, M., Imai, K., Takagi, M., et al. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.02.055 · Cited by 441

The role of IL-6 in host defence against infections: immunobiology and clinical implications

Rose-John, S., Winthrop, K., & Calabrese, L. (2017) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2017.83 · Cited by 424

Early B cell changes predict autoimmunity following combination immune checkpoint blockade

Das, R., Bar, N., Ferreira, M., Newman, A. M., Zhang, L., Bailur, J. K., Bacchiocchi, A., Kluger, H., Wei, W., Halaban, R., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96798 · Cited by 423

An Autoinflammatory Disease Due to Homozygous Deletion of the IL1RN Locus

Reddy, S. T., Jia, S., Geoffrey, R., Lorier, R., Suchi, M., Broeckel, U., Hessner, M. J., & Verbsky, J. W. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809568 · Cited by 408

Rheumatic and Musculoskeletal Immune‐Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature

Cappelli, L. C., Gutierrez, A. K., Bingham, C. O., & Shah, A. A. (2016) · Arthritis Care & Research · doi:10.1002/acr.23177 · Cited by 404

Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer

Berner, F., Bomze, D., Diem, S., Ali, O. H., Fässler, M., Ring, S., Niederer, R., Ackermann, C. J., Baumgaertner, P., Pikor, N., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.0402 · Cited by 395

Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma

Tarhini, A. A., Zahoor, H., Lin, Y., Malhotra, U., Sander, C., Butterfield, L. H., & Kirkwood, J. M. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0081-1 · Cited by 394

B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma

Griss, J., Bauer, W. M., Wagner, C., Simon, M., Chen, M., Grabmeier‐Pfistershammer, K., Maurer‐Granofszky, M., Roka, F., Penz, T., Bock, C., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12160-2 · Cited by 388

TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma

Bertrand, F., Montfort, A., Marcheteau, E., Imbert, C., Gilhodes, J., Filleron, T., Rochaix, P., Andrieu-Abadie, N., Levade, T., Meyer, N., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-02358-7 · Cited by 384

Interleukin-6 as a Therapeutic Target

Rossi, J., Lu, Z., Jourdan, M., & Klein, B. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2291 · Cited by 382

Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1–Based Immunotherapy

Lim, S. Y., Lee, J. H., Gide, T. N., Menzies, A. M., Guminski, A., Carlino, M. S., Breen, E. J., Yang, J. Y. H., Ghazanfar, S., Kefford, R. F., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2795 · Cited by 381

IL‐1 and IL‐1 regulatory pathways in cancer progression and therapy

Mantovani, A., Barajon, I., & Garlanda, C. (2018) · Immunological Reviews · doi:10.1111/imr.12614 · Cited by 376

PD-1 is a novel regulator of human B-cell activation

Thibult, M.-L., Mamessier, E., Gertner-Dardenne, J., Pastor, S., Just-Landi, S., Xerri, L., Chetaille, B., & Olive, D. (2013) · International Immunology · doi:10.1093/intimm/dxs098 · Cited by 365

Circulating CD21 low B cells in common variable immunodeficiency resemble tissue homing, innate-like B cells

Rakhmanov, M., Keller, B., Gutenberger, S., Foerster, C., Hoenig, M., Driessen, G. J. A., van der Burg, M., van Dongen, J. J. M., Wiech, E., Visentini, M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0901984106 · Cited by 334

Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade

Stroud, C. R., Hegde, A., Cherry, C., Naqash, A. R., Sharma, N., Addepalli, S., Cherukuri, S., Parent, T., Hardin, J., & Walker, P. (2019) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155217745144 · Cited by 331

IL-6 biology: implications for clinical targeting in rheumatic disease

Calabrese, L., & Rose-John, S. (2014) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2014.127 · Cited by 329

Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study

Wollenhaupt, J., Lee, E.-B., Curtis, J. R., Silverfield, J. C., Terry, K. K., Soma, K., Mojcik, C., DeMasi, R., Strengholt, S., Kwok, K. K., et al. (2019) · Arthritis Research & Therapy · doi:10.1186/s13075-019-1866-2 · Cited by 321

Induction and exacerbation of psoriasis with TNF-blockade therapy: A review and analysis of 127 cases

Ko, J., Gottlieb, A. B., & Kerbleski, J. F. (2008) · Journal of Dermatological Treatment · doi:10.1080/09546630802441234 · Cited by 314

Antitumor activity of murine tumor necrosis factor (TNF) against transplanted murine tumors and heterotransplanted human tumors in nude mice

Haranaka, K., Satomi, N., & Sakurai, A. (1984) · International Journal of Cancer · doi:10.1002/ijc.2910340219 · Cited by 312

Anakinra Therapy for Non-cancer Inflammatory Diseases

Cavalli, G., & Dinarello, C. A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01157 · Cited by 307

Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment

Tsukamoto, H., Fujieda, K., Miyashita, A., Fukushima, S., Ikeda, T., Kubo, Y., Senju, S., Ihn, H., Nishimura, Y., & Oshiumi, H. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0118 · Cited by 305

Immune Checkpoint Inhibitor-Associated Myocarditis

Ganatra, S., & Neilan, T. G. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0130 · Cited by 303

Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience

Mamlouk, O., Selamet, U., Machado, S., Abdelrahim, M., Glass, W. F., Tchakarov, A. S., Gaber, L. W., Lahoti, A., Workeneh, B., Chen, S., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0478-8 · Cited by 298

Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature

Abdel-Wahab, N., Safa, H., Abudayyeh, A., Johnson, D. H., Trinh, V. A., Zobniw, C. M., Lin, H., Wong, M. K., Abdelrahim, M., Gaber, A. O., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0585-1 · Cited by 294

Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients

Karachaliou, N., Gonzalez-Cao, M., Crespo, G., Drozdowskyj, A., Aldeguer, E., Gimenez-Capitan, A., Teixido, C., Molina-Vila, M. A., Viteri, S., De Los Llanos Gil, M., et al. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017749748 · Cited by 285

Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials.

Campbell, L., Chen, C., Bhagat, S., Parker, R., & Östör, A. (2011) · Rheumatology · doi:10.1093/rheumatology/keq343 · Cited by 280

Enterocolitis due to immune checkpoint inhibitors: a systematic review

Soularue, É., Lepage, P., Colombel, J. F., Coutzac, C., Faleck, D. M., Marthey, L., Collins, M., Chaput, N., Robert, C., & Carbonnel, F. (2018) · Gut · doi:10.1136/gutjnl-2018-316948 · Cited by 267

Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade

Jacquelot, N., Yamazaki, T., Roberti, M. P., Duong, C. P. M., Andrews, M. C., Verlingue, L., Ferrere, G., Becharef, S., Vétizou, M., Daillère, R., et al. (2019) · Cell Research · doi:10.1038/s41422-019-0224-x · Cited by 263

The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor?

Elkrief, A., Derosa, L., Kroemer, G., Zitvogel, L., & Routy, B. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz206 · Cited by 246

Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors

Moreira, A., Loquai, C., Pföhler, C., Kähler, K. C., Knauß, S., Heppt, M. V., Gutzmer, R., Dimitriou, F., Meier, F. E., Mitzel-Rink, H., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.09.033 · Cited by 242

Treatment Outcomes of Immune-Related Cutaneous Adverse Events

Phillips, G. S., Wu, J., Hellmann, M. D., Postow, M. A., Rizvi, N. A., Freites-Martinez, A., Chan, D., Dusza, S., Motzer, R. J., Rosenberg, J. E., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02141 · Cited by 241

Rheumatic immune-related adverse events from cancer immunotherapy

Calabrese, L. H., Calabrese, C. M., & Cappelli, L. C. (2018) · Nature Reviews Rheumatology · doi:10.1038/s41584-018-0074-9 · Cited by 237

Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire

Oh, D. Y., Cham, J., Zhang, L., Fong, G., Kwek, S. S., Klinger, M., Faham, M., & Fong, L. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2324 · Cited by 236

Interleukin-17 Contributes to the Pathogenesis of Autoimmune Hepatitis through Inducing Hepatic Interleukin-6 Expression

Zhao, L., Tang, Y., You, Z., Wang, Q., Liang, S., Han, X., Qiu, D., Wei, J., Liu, Y., Shen, L., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018909 · Cited by 236

NOD2, an intracellular innate immune sensor involved in host defense and Crohn's disease

Strober, W., & Watanabe, T. (2011) · Mucosal Immunology · doi:10.1038/mi.2011.29 · Cited by 231

Immunomodulation of autoimmune and inflammatory diseases with intravenous immunoglobulin

Ephrem, A., Misra, N., Hassan, G., Dasgupta, S., Delignat, S., Huyen, J. P. D. V., Chamat, S., Prost, F., Lacroix‐Desmazes, S., Kavery, S. V., et al. (2005) · Clinical and Experimental Medicine · doi:10.1007/s10238-005-0079-y · Cited by 231

Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation

Braaten, T. J., Brahmer, J. R., Forde, P. M., Le, D., Lipson, E. J., Naidoo, J., Schollenberger, M., Zheng, L., Bingham, C. O., Shah, A. A., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-216109 · Cited by 230

Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities

Subudhi, S. K., Aparicio, A., Gao, J., Zurita, A. J., Araujo, J. C., Logothetis, C. J., Tahir, S. A., Korivi, B. R., Slack, R. S., Vence, L., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1611421113 · Cited by 226

Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy

Esfahani, K., Buhlaiga, N., Thébault, P., Lapointe, R., Johnson, N. A., & Miller, W. H. (2019) · New England Journal of Medicine · doi:10.1056/nejmc1903064 · Cited by 224

mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and aging

Perl, A. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12756 · Cited by 218

Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study

Abu-Sbeih, H., Ali, F. S., Alsaadi, D., Jennings, J., Luo, W., Gong, Z., Richards, D. M., Charabaty, A., & Wang, Y. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0461-4 · Cited by 215

Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors

Fucà, G., Galli, G., Poggi, M., Lo Russo, G., Proto, C., Imbimbo, M., Ferrara, R., Zilembo, N., Ganzinelli, M., Sica, A., et al. (2019) · ESMO Open · doi:10.1136/esmoopen-2018-000457 · Cited by 209

Ipilimumab-associated Hepatitis

Johncilla, M. E., Misdraji, J., Pratt, D. S., Agoston, A. T., Lauwers, G. Y., Srivastava, A., & Doyle, L. A. (2015) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000453 · Cited by 208

Early Use of Systemic Corticosteroids in Patients with Advanced NSCLC Treated with Nivolumab

Scott, S. C., & Pennell, N. A. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.06.004 · Cited by 205

Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 Blockade

Esfahani, K., & Miller, W. H. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1703047 · Cited by 200

Interferons as pathogenic effectors in autoimmunity

Baccalà, R., Kono, D. H., & Theofilopoulos, A. N. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00252.x · Cited by 199

The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis

Suresh, K. S., Naidoo, J., Zhong, Q., Xiong, Y., Mammen, J. S., de Flores, M. D. V., Cappelli, L. C., Balaji, A., Palmer, T., Forde, P. M., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci128654 · Cited by 198

Targeting the tumor microenvironment

Bournazou, E., & Bromberg, J. (2013) · JAK-STAT · doi:10.4161/jkst.23828 · Cited by 196

Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis

Johnson, D. H., Zobniw, C. M., Trinh, V. A., Ma, J., Bassett, R. L., Abdel‐Wahab, N., Anderson, J. E., Davis, J. E., Joseph, J., Uemura, M. I., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0412-0 · Cited by 196

Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors

de Moel, E. C., Rozeman, E. A., Kapiteijn, E. H., Verdegaal, E. M. E., Grummels, A., Bakker, J. A., Huizinga, T. W. J., Haanen, J. B., Toes, R. E. M., & van der Woude, D. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0245 · Cited by 191

Immune dysregulation in cancer patients developing immune-related adverse events

Khan, S., Khan, S. A., Luo, X., Fattah, F. J., Saltarski, J., Gloria-McCutchen, Y., Lu, R., Xie, Y., Li, Q., Wakeland, E., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-018-0155-1 · Cited by 186

Systemic use of tumor necrosis factor alpha as an anticancer agent

Roberts, N. J., Zhou, S., Diaz, L. A., & Holdhoff, M. (2011) · Oncotarget · doi:10.18632/oncotarget.344 · Cited by 178

JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer

Lu, C., Talukder, A. M., Savage, N. M., Singh, N., & Liu, K. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1291106 · Cited by 177

Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions

Nishimoto, N., Ito, K., & Takagi, N. (2010) · Modern Rheumatology · doi:10.3109/s10165-010-0279-5 · Cited by 172

Resolution of Severe Ipilimumab-Induced Hepatitis After Antithymocyte Globulin Therapy

Chmiel, K., Suan, D., Liddle, C., Nankivell, B. J., Ibrahim, R. A., Bautista, C., Thompson, J. F., Fulcher, D. A., & Kefford, R. F. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2206 · Cited by 163

Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma

Shoushtari, A. N., Friedman, C. F., Navid-Azarbaijani, P., Postow, M. A., Callahan, M. K., Momtaz, P., Panageas, K. S., Wolchok, J. D., & Chapman, P. B. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.2391 · Cited by 157

Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions

Nishimoto, N., Ito, K., & Takagi, N. (2010) · Modern Rheumatology · doi:10.1007/s10165-010-0279-5 · Cited by 154

IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in mouse model

Liu, H., Shen, J., & Lü, K. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.02.128 · Cited by 150

Oncolysis without viruses — inducing systemic anticancer immune responses with local therapies

Kepp, O., Marabelle, A., Zitvogel, L., & Kroemer, G. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0272-7 · Cited by 145

Concurrent therapy with immune checkpoint inhibitors and TNFα blockade in patients with gastrointestinal immune-related adverse events

Badran, Y. R., Cohen, J. V., Brastianos, P. K., Parikh, A. R., Hong, T. S., & Dougan, M. L. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0711-0 · Cited by 143

Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1

Mammen, A. L., Rajan, A., Pak, K. S., Lehky, T., Casciola-Rosen, L. A., Donahue, R. N., Lepone, L. M., Ζεκερίδου, Α., Pittock, S. J., Hassan, R., et al. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-213777 · Cited by 137

Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy

Shiuan, E. F., Beckermann, K. E., Özgün, A., Kelly, C. M., McKean, M. A., McQuade, J. L., Thompson, M. A., Puzanov, I. J., Greer, J. P., Rapisuwon, S., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0210-0 · Cited by 135

Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer

Godwin, J. L., Jaggi, S., Sirisena, I., Sharda, P., Rao, A. D., Mehra, R., & Veloski, C. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0245-2 · Cited by 135

Evaluation of serum IL-17 levels during ipilimumab therapy: Correlation with colitis.

Callahan, M. K., Yang, A., Tandon, S., Xu, Y., Subudhi, S. K., Roman, R., Heine, A. I., Pogoriler, E., Kuk, D., Panageas, K., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.2505 · Cited by 129

Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors

Gowen, M. F., Giles, K. M., Simpson, D., Tchack, J., Zhou, H., Moran, U., Dawood, Z., Pavlick, A. C., Hu, S., Wilson, M. A., et al. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1452-4 · Cited by 125

Transcriptional Complex Formation of c-Fos, STAT3, and Hepatocyte NF-1α Is Essential for Cytokine-Driven C-Reactive Protein Gene Expression

Nishikawa, T., Hagihara, K., Serada, S., Isobe, T., Matsumura, A., Song, J., Tanaka, T., Kawase, I., Naka, T., & Yoshizaki, K. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.5.3492 · Cited by 119

Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy

Tay, R. Y., Blackley, E., McLean, C., Moore, M., Bergin, P., Gill, S., & Haydon, A. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.253 · Cited by 119

A balance of interleukin-12 and -23 in cancer

Ngiow, S. F., Teng, M. W. L., & Smyth, M. J. (2013) · Trends in Immunology · doi:10.1016/j.it.2013.07.004 · Cited by 117

Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma

Albiges, L. K., Chamming’s, F., Duclos, B., Stern, M., Motzer, R. J., Ravaud, A., & Camus, P. (2012) · Annals of Oncology · doi:10.1093/annonc/mds115 · Cited by 113

IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from Immunotherapy

Johnson, D., Patel, A. B., Uemura, M. I., Trinh, V. A., Jackson, N., Zobniw, C. M., Tetzlaff, M. T., Hwu, P., Curry, J. L., & Diab, A. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0682 · Cited by 111

Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation

Esfahani, K., Al-Aubodah, T.-A., Thebault, P., Lapointe, R., Hudson, M., Johnson, N. A., Baran, D., Bhulaiga, N., Takano, T., Cailhier, J.-F., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12628-1 · Cited by 109

A Multidisciplinary Toxicity Team for Cancer Immunotherapy–Related Adverse Events

Naidoo, J., Zhang, J., Lipson, E. J., Forde, P. M., Suresh, K. S., Moseley, K. F., Mehta, S., Kwatra, S. G., Parian, A. M., Kim, A. K., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.7268 · Cited by 107

Natalizumab may control immune checkpoint inhibitor–induced limbic encephalitis

Hottinger, A. F., Micheli, R. D., Guido, V., Karampera, A., Hagmann, P., & Pasquier, R. D. (2018) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000439 · Cited by 105

Advanced model systems and tools for basic and translational human immunology

Wagar, L. E., DiFazio, R. M., & Davis, M. M. (2018) · Genome Medicine · doi:10.1186/s13073-018-0584-8 · Cited by 104

Intravenous immunoglobulin as clinical immune-modulating therapy

Gilardin, L., Bayry, J., & Kaveri, S. V. (2015) · Canadian Medical Association Journal · doi:10.1503/cmaj.130375 · Cited by 103

Update on interleukin-17: a role in the pathogenesis of inflammatory arthritis and implication for clinical practice

Miossec, P. (2017) · RMD Open · doi:10.1136/rmdopen-2016-000284 · Cited by 96

Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis

Abu‐Sbeih, H., Herrera, L. N., Tang, T., Altan, M., Chaftari, A., Okhuysen, P. C., Jenq, R. R., & Wang, Y. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0714-x · Cited by 95

Polymyalgia rheumatica-like syndrome from checkpoint inhibitor therapy: case series and systematic review of the literature

Calabrese, C. M., Cappelli, L. C., Kostine, M., Kirchner, E., Braaten, T. J., & Calabrese, L. H. (2019) · RMD Open · doi:10.1136/rmdopen-2019-000906 · Cited by 89

Re-examining the Nature and Function of Self-Reactive T cells

Richards, D. M., Kyewski, B., & Feuerer, M. (2016) · Trends in Immunology · doi:10.1016/j.it.2015.12.005 · Cited by 81

Innate Lymphoid Cells: Expression of PD-1 and Other Checkpoints in Normal and Pathological Conditions

Mariotti, F. R., Quatrini, L., Munari, E., Vacca, P., & Moretta, L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00910 · Cited by 75

Correlation of absolute and relative eosinophil counts with immune-related adverse events in melanoma patients treated with ipilimumab.

Schindler, K., Harmankaya, K., Kuk, D., Mangana, J., Michielin, O. A., Höeller, C., Dummer, R., Pehamberger, H., Wolchok, J. D., & Postow, M. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.9096 · Cited by 71

How steroids steer T cells

Libert, C., & Dejager, L. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.04.041 · Cited by 69

A severe case of neuro-Sjögren’s syndrome induced by pembrolizumab

Ghosn, J., Vicino, A., Michielin, O. A., Coukos, G., Küntzer, T., & Obéid, M. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0429-4 · Cited by 60

Rheumatologic symptoms in oncologic patients on PD-1 inhibitors

Kuswanto, W. F., MacFarlane, L. A., Gedmintas, L., Mulloy, A., Choueiri, T. K., & Bermas, B. L. (2017) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2017.10.018 · Cited by 58

Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports

Yoshino, K., Nakayama, T., Ito, A., Sato, E., & Kitano, S. (2019) · BMC Cancer · doi:10.1186/s12885-019-6138-7 · Cited by 57

Rapamycin inhibition of eosinophil differentiation attenuates allergic airway inflammation in mice

Hua, W., Liu, H., Xia, L., Tian, B., Huang, H., Chen, Z., Ju, Z., Li, W., Chen, Z., & Shen, H. (2015) · Respirology · doi:10.1111/resp.12554 · Cited by 54

Interleukin-6 as one of the potential mediators of immune-related adverse events in non-small cell lung cancer patients treated with immune checkpoint blockade: evidence from a case report

Naqash, A., Yang, L. V., Sanderlin, E., Atwell, D. C., & Walker, P. (2017) · Acta oncologica · doi:10.1080/0284186x.2017.1406668 · Cited by 53

Resolution of ipilimumab induced severe hepatotoxicity with triple immunosuppressants therapy

Ahmed, T., Pandey, R., Shah, B., & Black, J. (2015) · BMJ Case Reports · doi:10.1136/bcr-2014-208102 · Cited by 50

Corticosteroids influence the mortality and morbidity of acute critical illness

Rady, M. Y., Johnson, D. J., Patel, B. M., Larson, J. S., & Helmers, R. A. (2006) · Critical Care · doi:10.1186/cc4971 · Cited by 50

Serum IL-6 and CRP as prognostic factors in melanoma patients receiving single agent and combination checkpoint inhibition.

Weber, J. S., Tang, H. T., Hippeli, L., Qian, M., Wind‐Rotolo, M., Larkin, J., Wolchok, J. D., Sznol, M., Robert, C., Woods, D. M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.100 · Cited by 47

Corticosteroids and infliximab impair the performance of interferon-γ release assays used for diagnosis of latent tuberculosis

Edwards, A. J., Gao, Y., Allan, R. N., Ball, D., de Graaf, H., Coelho, T. A. F., Clifford, V., Curtis, N. C., Williams, A. P., Faust, S. N., et al. (2017) · Thorax · doi:10.1136/thoraxjnl-2016-209397 · Cited by 44

Acute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximab

Zhang, H. C., Luo, W., & Wang, Y. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0532-1 · Cited by 41

Fatal Myocarditis and Rhabdomyositis in a Patient with Stage Iv Melanoma Treated with Combined Ipilimumab and Nivolumab

Saibil, S. D., Bonilla, L., Majeed, H., Sotov, V., Hogg, D., Chappell, M. A., Cybulsky, M. I., & Butler, M. O. (2019) · Current Oncology · doi:10.3747/co.26.4381 · Cited by 38

B cells sustain inflammation and predict response to immune checkpoint blockade in human melanomaPreprint

Griss, J., Bauer, W. M., Wagner, C., Maurer‐Granofszky, M., Simon, M., Chen, M., Steinberger, P., Grabmeier‐Pfistershammer, K., Roka, F., Penz, T., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/478735 · Cited by 37

Structure-Function Analysis of the p35 Subunit of Mouse Interleukin 12

Zou, J. J., Schoenhaut, D. S., Carvajal, D. M., Warrier, R. R., Presky, D. H., Gately, M. K., & Gubler, U. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.11.5864 · Cited by 37

Resolution of Infliximab-Refractory Nivolumab-Induced Acute Severe Enterocolitis After Cyclosporine Treatment in a Patient with Non-Small Cell Lung Cancer

Iyoda, T., Kurita, N., Takada, A., Watanabe, H., & Ando, M. (2018) · American Journal of Case Reports · doi:10.12659/ajcr.908570 · Cited by 36

Incidence and clinical pattern of immune related adverse effects (irAE) due to immune checkpoint inhibitors (ICI).

Thapa, B., Roopkumar, J., Kim, A. S., Gervaso, L., Patil, P. D., Calabrese, C. M., Khorana, A. A., & Funchain, P. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.e14151 · Cited by 36

Varied immuno-related adverse events induced by immune-check point inhibitors — Nivolumab-associated psoriasiform dermatitis related with increased serum level of interleukin-6 —

Okiyama, N., & Tanaka, R. (2017) · Japanese Journal of Clinical Immunology · doi:10.2177/jsci.40.95 · Cited by 34

Safety of Tocilizumab in Rheumatoid Arthritis Patients with Resolved Hepatitis B Virus Infection: Data from Real-World Experience

Ahn, S. S., Jung, S. M., Song, J. J., Park, Y., Park, J. Y., & Lee, S. (2018) · Yonsei Medical Journal · doi:10.3349/ymj.2018.59.3.452 · Cited by 32

Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events

Hoefsmit, E. P., Rozeman, E. A., Haanen, J. B. A. G., & Blank, C. U. (2019) · ESMO Open · doi:10.1136/esmoopen-2018-000472 · Cited by 29

Resolution of Pembrolizumab-Associated Steroid-Refractory Lichenoid Dermatitis with Cyclosporine

Fixsen, E., Patel, J., Selim, M. A., & Kheterpal, M. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0531 · Cited by 28

Increment Thresholds for Two Nonidentical Flashes*

Herrick, R. M., & Theisen, C. J. (1972) · Journal of the Optical Society of America · doi:10.1364/josa.62.000588 · Cited by 25

JAK2 Inhibitor SAR302503 Abrogates PD-L1 Expression and Targets Therapy-Resistant Non–small Cell Lung Cancers

Pitroda, S. P., Stack, M. E., Liu, G.-F., Song, S.-S., Chen, L. L., Liang, H. L., Parekh, A. D., Huang, X., Roach, P., Posner, M. C., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0667 · Cited by 23

mTOR complexes differentially orchestrates eosinophil development in allergy

Zhu, C., Xia, L., Li, F., Zhou, L., Weng, Q., Li, Z., Wu, Y., Mao, Y., Zhang, C., Wu, Y., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-25358-z · Cited by 23

The interaction between environmental triggers and epigenetics in autoimmunity

Richardson, B. (2018) · Clinical Immunology · doi:10.1016/j.clim.2018.04.005 · Cited by 22

Tumor Necrosis Factor and the consequences of its ablation in vivo

Efimov, G. A., Kruglov, A., Tillib, S. V., Kuprash, D. V., & Nedospasov, S. A. (2009) · Molecular Immunology · doi:10.1016/j.molimm.2009.01.007 · Cited by 21

A multidisciplinary toxicity team for cancer immunotherapy-related adverse events.

Naidoo, J., Cappelli, L. C., Lipson, E. J., Forde, P. M., Sharfman, W. H., Zhang, J., Mammen, J., Moseley, K. F., Suresh, K. S., Mehta, S., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.6538 · Cited by 20

Myocarditis associated with infliximab

Slattery, E., Ismail, N., Sheridan, J., Eustace, K., Harewood, G. C., & Patchett, S. E. (2010) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21546 · Cited by 20

Biomarkers to predict immune-related adverse events with checkpoint inhibitors.

Head, L., Gorden, N. T., Gulick, R. J. V., Amato, C. M., Frazer‐Abel, A. A., Robinson, W. A., Holers, V. M., Messersmith, W. A., & Davis, S. L. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.8_suppl.131 · Cited by 19

Correction to: The pathogenicity of Th17 cells in autoimmune diseases

Yasuda, K., Takeuchi, Y., & Hirota, K. (2019) · Seminars in Immunopathology · doi:10.1007/s00281-019-00746-3 · Cited by 17

Myalgia and Arthralgia Immune-related Adverse Events (irAEs) in Patients With Genitourinary Malignancies Treated With Immune Checkpoint Inhibitors

Ornstein, M. C., Calabrese, C. M., Wood, L. S., Kirchner, E., Profusek, P., Allman, K. D., Martin, A. M., Kontzias, A., Grivas, P. D., Garcia, J. A., et al. (2019) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2019.01.021 · Cited by 15

Inflammatory Arthritis Induced by Pembrolizumab in a Patient With Head and Neck Squamous Cell Carcinoma

Spathas, N., Economopoulou, P., Cheila, M., Kotsantis, I., Fanouriakis, A., Kassara, D., & Psyrri, A. K. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00409 · Cited by 15

Refractory Neutropenia Secondary to Dual Immune Checkpoint Inhibitors That Required Second-Line Immunosuppression

Meti, N., Petrogiannis‐Haliotis, T., & Esfahani, K. (2018) · Journal of Oncology Practice · doi:10.1200/jop.18.00177 · Cited by 14

New onset or exacerbation of uveitis with infliximab: paradoxical effects?

Iwahashi, C., Ono, H., Haruta, M., Minami, T., Mashimo, H., Shimojo, H., & Ohguro, N. (2019) · BMJ Open Ophthalmology · doi:10.1136/bmjophth-2018-000250 · Cited by 14

Cold agglutinin disease as a new immune-related adverse event associated with anti-PD-L1s and its treatment with rituximab

Dutertre, M., de Menthon, M., Noël, N., Albiges, L. K., & Lambotte, O. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.01.009 · Cited by 12

Eosinophilia during treatment of immune checkpoint inhibitors (ICIs) to predict succeeding onset of immune-related adverse events (irAEs).

Kizawa, R., Miura, Y., Oda, Y., Nagaoka, Y., Ozaki, Y., Kondoh, C. N., Moriguchi, S., Takahashi, Y., Ogawa, K., Tanabe-Hashimoto, Y., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.e14110 · Cited by 11

Programmed Cell Death Ligand 1–Induced Coma From Diffuse Cerebritis

Desforges, P., Esfahani, K., & Bouganim, N. (2017) · Journal of Oncology Practice · doi:10.1200/jop.2017.024992 · Cited by 5

The ImmunoTOX multidisciplinary board: A descriptive study of collaborative management of immune-related adverse events

Michot, J., Lappara, A., Simonaggio, A., Danlos, F. X., Belkhir, R., Collins, M., Berdelou, A., Cauquil, C. A., Edhery, S., Pavec, J. L., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz265.003 · Cited by 4

[Photocoagulation of papillary neovascularization].

Bonnet, M. (1980) · PubMed · Cited by 2

Correlation of immune-related adverse events with peripheral baseline immune markers and overall survival in patients with metastatic melanoma on ipilimumab and chemotherapy.

Esfahani, K., Thébault, P., Lapointe, R., Jamal, R., & Miller, W. H. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.9561 · Cited by 2

[Phagocyte and antitoxic immunity in suppurative surgical diseases in children].

Ostrovskiĭ, A. D., & Ia, S. (1969) · PubMed · Cited by 1

Hallmarks of response, resistance, and toxicity to immune checkpoint blockade

Morad, G., Helmink, B. A., Sharma, P., & Wargo, J. A. (2021) · Cell · doi:10.1016/j.cell.2021.09.020 · Cited by 1,648

Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial

Routy, B., Lenehan, J. G., Miller, W. H., Jamal, R., Messaoudene, M., Daisley, B. A., Hes, C., Al, K. F., Martinez-Gili, L., Punčochář, M., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02453-x · Cited by 526

Immune-related adverse events of immune checkpoint inhibitors: a review

Yin, Q., Wu, L., Han, L., Zheng, X., Tong, R., Li, L., Bai, L., & Bian, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1167975 · Cited by 495

Immunologic tumor microenvironment modulators for turning cold tumors hot

Khosravi, G. R., Mostafavi, S., Bastan, S., Ebrahimi, N., Gharibvand, R. S., & Eskandari, N. (2024) · 癌症：英文版 · doi:10.1002/cac2.12539 · Cited by 403

Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity

Hailemichael, Y., Johnson, D. H., Abdel‐Wahab, N., Foo, W. C., Bentebibel, S.-E., Daher, M., Haymaker, C., Wani, K., Saberian, C., Ogata, D., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.04.004 · Cited by 372

Personalized treatment of immune-related adverse events — balance is required

Martins, F., & Obéid, M. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0400-4 · Cited by 7

Pathological perspectives on immune-related adverse events

Kubo, T., Morita, R., Sasaki, K., Shijubou, N., Murata, K., Tsukahara, T., Torigoe, T., & Hirohashi, Y. (2026) · Immunological Medicine · doi:10.1080/25785826.2026.2689102

Comprehensive management of immune-related adverse events: predictive strategies, mechanistic insights, and therapeutic approaches

Murakami, K. (2026) · Immunological Medicine · doi:10.1080/25785826.2026.2664951

Clinical and translational attributes of immune-related adverse events

Suijkerbuijk, K. P. M., van Eijs, M. J. M., van Wijk, F., & Eggermont, A. M. M. (2024) · Nature Cancer · doi:10.1038/s43018-024-00730-3 · Cited by 136

Immunologic adverse events from immune checkpoint therapy

Richter, M. D., Hughes, G. C., Chung, S. H., Ezeanuna, M., Singh, N., & Thompson, J. A. (2020) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2020.101511 · Cited by 6